Abstract：
BACKGROUND: Ribonucleotide reductase subunit M2 (RRM2) plays a key role in cell and hepatitis B virus (HBV) replication. Nevertheless, its clinical implications for managing liver diseases have been inadequately studied.
METHODS: A total of 412 participants were enrolled, including 60 healthy control individuals, 55 patients with chronic hepatitis B (CHB), 173 patients with cirrhosis, and 124 patients with hepatocellular carcinoma (HCC). Serum RRM2 was measured via ELISA.
RESULTS: The level of serum RRM2 in patients with CHB, cirrhosis, and HCC was higher than that in healthy controls (P < .05). A large difference in serum RRM2 was found between HBV-related and non-HBV-related patients in the cirrhosis group (P < .001), compared with the difference between HBV-related HCC and non-HBV-related HCC (P = .86). In the HBV-related cirrhosis group, the serum RRM2 level showed significant positive correlations with HBV DNA, hepatitis B surface antigen, hepatitis B e antigen, Child-Pugh scores, and MELD scores and played a strong role in diagnosing HBV-related cirrhosis in CHB, compared with fibrosis-4 score and aspartate aminotransferase-to-platelet ratio index.
CONCLUSIONS: Serum RRM2 is a reliable biomarker for accurate HBV-related cirrhosis diagnosis and evaluation. Also, serum RRM2 could reflect the expression state of HBV replication in patients with HBV-related cirrhosis.
METHODS: A total of 412 participants were enrolled, including 60 healthy control individuals, 55 patients with chronic hepatitis B (CHB), 173 patients with cirrhosis, and 124 patients with hepatocellular carcinoma (HCC). Serum RRM2 was measured via ELISA.
RESULTS: The level of serum RRM2 in patients with CHB, cirrhosis, and HCC was higher than that in healthy controls (P < .05). A large difference in serum RRM2 was found between HBV-related and non-HBV-related patients in the cirrhosis group (P < .001), compared with the difference between HBV-related HCC and non-HBV-related HCC (P = .86). In the HBV-related cirrhosis group, the serum RRM2 level showed significant positive correlations with HBV DNA, hepatitis B surface antigen, hepatitis B e antigen, Child-Pugh scores, and MELD scores and played a strong role in diagnosing HBV-related cirrhosis in CHB, compared with fibrosis-4 score and aspartate aminotransferase-to-platelet ratio index.
CONCLUSIONS: Serum RRM2 is a reliable biomarker for accurate HBV-related cirrhosis diagnosis and evaluation. Also, serum RRM2 could reflect the expression state of HBV replication in patients with HBV-related cirrhosis.
摘要：
背景：核糖核苷酸还原酶亚基M2（RRM2）在细胞和乙型肝炎病毒（HBV）复制中起关键作用。然而，其对肝脏疾病管理的临床意义尚未得到充分研究。
方法：共纳入412名参与者，包括60名健康对照者，55例慢性乙型肝炎（CHB），173例肝硬化患者，和124例肝细胞癌（HCC）患者。通过ELISA测量血清RRM2。
结果：CHB患者血清RRM2水平，肝硬化,HCC高于健康对照组（P<0.05）。肝硬化组HBV相关和非HBV相关患者之间的血清RRM2有很大差异（P<0.001），HBV相关HCC和非HBV相关HCC之间的差异（P=0.86）。在HBV相关性肝硬化组中，血清RRM2水平与HBVDNA呈显著正相关,乙型肝炎表面抗原,乙型肝炎e抗原，Child-Pugh分数,和MELD评分，并在CHB中诊断HBV相关性肝硬化方面发挥了重要作用，与纤维化-4评分和天冬氨酸转氨酶/血小板比值指数比较。
结论：血清RRM2是准确诊断和评估HBV相关性肝硬化的可靠生物标志物。此外，血清RRM2可以反映HBV相关性肝硬化患者HBV复制的表达状态。
方法：共纳入412名参与者，包括60名健康对照者，55例慢性乙型肝炎（CHB），173例肝硬化患者，和124例肝细胞癌（HCC）患者。通过ELISA测量血清RRM2。
结果：CHB患者血清RRM2水平，肝硬化,HCC高于健康对照组（P<0.05）。肝硬化组HBV相关和非HBV相关患者之间的血清RRM2有很大差异（P<0.001），HBV相关HCC和非HBV相关HCC之间的差异（P=0.86）。在HBV相关性肝硬化组中，血清RRM2水平与HBVDNA呈显著正相关,乙型肝炎表面抗原,乙型肝炎e抗原，Child-Pugh分数,和MELD评分，并在CHB中诊断HBV相关性肝硬化方面发挥了重要作用，与纤维化-4评分和天冬氨酸转氨酶/血小板比值指数比较。
结论：血清RRM2是准确诊断和评估HBV相关性肝硬化的可靠生物标志物。此外，血清RRM2可以反映HBV相关性肝硬化患者HBV复制的表达状态。
